<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 20 Apr 2021 23:25:28 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>集采后时代 - 他汀类药物还剩多少余量？</title><link>https://mp.weixin.qq.com/s/3Fhg-rE72Ztm1MJcgUCv5w</link><description></description><content:encoded><![CDATA[集采后时代 - 他汀类药物还剩多少余量？]]></content:encoded><pubDate>Tue, 20 Apr 2021 21:38:18 +0800</pubDate></item><item><title>知名重磅注射液，再现降价潮！</title><link>https://mp.weixin.qq.com/s/hj5uSDl0vmGJvEf06BlA5g</link><description></description><content:encoded><![CDATA[知名重磅注射液，再现降价潮！]]></content:encoded><pubDate>Tue, 20 Apr 2021 21:38:18 +0800</pubDate></item><item><title>国采非中选药价格调整，大批原研产品在列...</title><link>https://mp.weixin.qq.com/s/iMTh08VbJwT0Jk9NHEFghQ</link><description></description><content:encoded><![CDATA[国采非中选药价格调整，大批原研产品在列...]]></content:encoded><pubDate>Tue, 20 Apr 2021 21:38:18 +0800</pubDate></item><item><title>「4+7」品种出现供应短缺？</title><link>https://mp.weixin.qq.com/s/m1bmJ1gq6D4X5o_RJnT9Rw</link><description></description><content:encoded><![CDATA[「4+7」品种出现供应短缺？]]></content:encoded><pubDate>Tue, 20 Apr 2021 21:38:18 +0800</pubDate></item><item><title>（2021.4.19）4品种首家过评，涉及齐鲁、华东、华海…</title><link>https://mp.weixin.qq.com/s/kG0NGRTJQN__ISS7XiPa2g</link><description></description><content:encoded><![CDATA[（2021.4.19）4品种首家过评，涉及齐鲁、华东、华海…]]></content:encoded><pubDate>Mon, 19 Apr 2021 21:41:06 +0800</pubDate></item><item><title>279品规集采来袭，分A、B两组展开角逐...</title><link>https://mp.weixin.qq.com/s/A2Z50zJR5jyTdbLAY7HFYQ</link><description></description><content:encoded><![CDATA[279品规集采来袭，分A、B两组展开角逐...]]></content:encoded><pubDate>Mon, 19 Apr 2021 21:41:06 +0800</pubDate></item><item><title>一大批过评药新增挂网（附：最新采购价）</title><link>https://mp.weixin.qq.com/s/zTUfqV8BuaqqSf2ZM7EeiQ</link><description></description><content:encoded><![CDATA[一大批过评药新增挂网（附：最新采购价）]]></content:encoded><pubDate>Mon, 19 Apr 2021 21:41:06 +0800</pubDate></item><item><title>基药目录调整，传出最新消息！</title><link>https://mp.weixin.qq.com/s/fbSewjMc9BHbK5Q4mXzzCQ</link><description></description><content:encoded><![CDATA[基药目录调整，传出最新消息！]]></content:encoded><pubDate>Mon, 19 Apr 2021 21:41:06 +0800</pubDate></item><item><title>【项目合作】热门糖尿病药，与二甲双胍组个CP，杀过去！</title><link>https://mp.weixin.qq.com/s/lAtmD9E7S_lsOTMNO1yy-Q</link><description></description><content:encoded><![CDATA[【项目合作】热门糖尿病药，与二甲双胍组个CP，杀过去！]]></content:encoded><pubDate>Sun, 18 Apr 2021 22:16:20 +0800</pubDate></item><item><title>索马鲁肽VS同类药物，一场豪赌！</title><link>https://mp.weixin.qq.com/s/2H7lBtSdhiqhzPmMECFViw</link><description></description><content:encoded><![CDATA[索马鲁肽VS同类药物，一场豪赌！]]></content:encoded><pubDate>Sun, 18 Apr 2021 22:16:20 +0800</pubDate></item><item><title>李永康精讲：“药品研发分析和QC实验室合规管理的优化与创新” 专题研修班</title><link>https://mp.weixin.qq.com/s/ADRZ1Al0QdeeR5nCIIsfAQ</link><description></description><content:encoded><![CDATA[李永康精讲：“药品研发分析和QC实验室合规管理的优化与创新” 专题研修班]]></content:encoded><pubDate>Sun, 18 Apr 2021 22:16:20 +0800</pubDate></item><item><title>医药销售被裁！药都能卖出去，还怕自己卖不出去？</title><link>https://mp.weixin.qq.com/s/jPfAU4o7SKChDOFSSLsq3g</link><description></description><content:encoded><![CDATA[医药销售被裁！药都能卖出去，还怕自己卖不出去？]]></content:encoded><pubDate>Sat, 17 Apr 2021 21:43:42 +0800</pubDate></item><item><title>3月一致性评价：申报量回升，28过评品种决出首家…</title><link>https://mp.weixin.qq.com/s/quFamD30BkQHQZT6t2axlA</link><description></description><content:encoded><![CDATA[3月一致性评价：申报量回升，28过评品种决出首家…]]></content:encoded><pubDate>Fri, 16 Apr 2021 21:43:13 +0800</pubDate></item><item><title>潜力骨松症用药，原研一家独大，破局更待何时？</title><link>https://mp.weixin.qq.com/s/xrPBtfBpYh-BF2OEm1sltA</link><description></description><content:encoded><![CDATA[潜力骨松症用药，原研一家独大，破局更待何时？]]></content:encoded><pubDate>Fri, 16 Apr 2021 21:43:13 +0800</pubDate></item><item><title>第四十二批参比目录公示，62个新增（增补），8个不通过</title><link>https://mp.weixin.qq.com/s/R54BQUUvca29OceLBlBbIg</link><description></description><content:encoded><![CDATA[第四十二批参比目录公示，62个新增（增补），8个不通过]]></content:encoded><pubDate>Fri, 16 Apr 2021 21:43:13 +0800</pubDate></item><item><title>注意！这些药品将被暂停采购</title><link>https://mp.weixin.qq.com/s/2W6d9ID-4sQhFzknyg2rzw</link><description></description><content:encoded><![CDATA[注意！这些药品将被暂停采购]]></content:encoded><pubDate>Fri, 16 Apr 2021 21:43:13 +0800</pubDate></item><item><title>第五批国采报量开始，开标之日近在咫尺...</title><link>https://mp.weixin.qq.com/s/7FdvLryH5EvENT0IrRIEWg</link><description></description><content:encoded><![CDATA[第五批国采报量开始，开标之日近在咫尺...]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:02:27 +0800</pubDate></item><item><title>（2021.4.15）最新一致性评价目录来了！</title><link>https://mp.weixin.qq.com/s/rPfwqm1xjEA492Zq0Pbu0Q</link><description></description><content:encoded><![CDATA[（2021.4.15）最新一致性评价目录来了！]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:02:27 +0800</pubDate></item><item><title>知名大药企涉嫌垄断，被罚7.64亿元！</title><link>https://mp.weixin.qq.com/s/mbDiz6kgv6QaxFhDMJ0y9Q</link><description></description><content:encoded><![CDATA[知名大药企涉嫌垄断，被罚7.64亿元！]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:02:27 +0800</pubDate></item><item><title>仿制药制剂：工艺研究和工艺验证</title><link>https://mp.weixin.qq.com/s/kO6QHM6Oyvin8ImvM57cHA</link><description></description><content:encoded><![CDATA[仿制药制剂：工艺研究和工艺验证]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:02:27 +0800</pubDate></item></channel></rss>